Ncardia launches Cellistic, an iPSC cell therapy CDMO
Ncardia launches CellisticTM, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.
GOSSELIES, BELGIUM (April 19, 2022) - Ncardia has launched a new business, CellisticTM to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including the development of robust cell-specific manufacturing platforms.
The development of cell therapies derived from iPSCs offers the possibility of effective treatments for many diseases and reducing the cost and complexity of current autologous cell therapies. However, there are a number of challenges that must be addressed in order to deliver on the promise of large-scale allogeneic cell therapy. Creating an effective therapeutic not only requires intimate knowledge of the disease being targeted, but also deep understanding of the processes required to generate the most relevant cell type to treat the disease, and the expertise to scale that process to clinically and commercially feasible volumes. These differentiation and expansion activities present unique challenges and require unique experience and skills which, until the launch of Cellistic TM have not been available to therapeutic developers without extensive investment in internal capabilities.
Source: Ncardia
